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ABSTRACT 
Desmin is a major intermediate filament of muscle cells, serving to transmit 
mechanical forces and propagate mechanochemical signals, to coordinate 
contraction and relaxation cycles, and to stabilize the positioning of cellular 
organelles, e.g. mitochondria. Around 70 desmin gene mutations have been 
reported in conjunction with desmin-related myopathy. Desmin-related myopathy 
can be described as pathophysiological complex, accompanied by desmin 
intracellular aggregate accumulation and impairment of desmin interactions with 
structural proteins, signal molecules, and cell organelles. However, the precise 
molecular mechanism underlying desmin-related myopathy have not been 
described yet. There are speculations if it is connected with toxic effects of desmin 
aggregates or with violation of desmin mechanotransduction functions.  
The general aim of the present PhD project was to extend existing knowledge about 
the molecular machinery on how desmin gene mutations lead to the development 
of desmin-related myopathy, with an emphasis on development of 
cardiomyopathies. To address this aim the following research questions were 
stated: (i) genetic study of a group of patients with cardiomyopathies in order to 
describe novel mutations in the desmin gene, and to assess the frequency of DES 
A213V; (ii) genetic study by means of next-generation sequencing approach of a 
group of patients with idiopathic restrictive cardiomyopathy in order to describe 
novel genetic variants associated with disease; (iii) functional study of desmin gene 
point mutations effect on mitochondrial properties. 
The main findings regarding genetic background were: (i) DES A213V represents a 
disease-modifying polymorphism, rather than disease-related mutation, since it 
was found both in patients and healthy donors; (ii) combination of disease-related–
disease-modifying or disease-related–disease-related genetic variants, rather than 
single disease-related mutation, determined the development of idiopathic 
restrictive cardiomyopathy. Most proteins of these combinations belonged to four 
functional groups: sarcomeric contractile proteins, mechanosensing Z-disc 
proteins, nuclear membrane, and outer mitochondrial membrane proteins. 
Functional studies of the impact of desmin mutations on mitochondria showed that 
aggregate-prone mutations decreased mitochondrial calcium uptake, as well as 
depressed maximal oxygen consumption rate and spare respiratory capacity. In 
contrast, non-aggregate-prone mutations did not disturb mitochondrial calcium. 
They did, however, result in the reduction of maximal oxygen consumption rate 
and affected spare respiratory capacity.  
To conclude, (i) distortion of desmin mechanotransduction functions plays an 
important role in desmin-related myopathy onset, affecting mitochondrial 
properties; (ii) combination of mutations in genes encoding sarcomeric contractile 
and mechanosensing proteins, rather than a single mutation, predisposes to the 
development of cardiomyopathy. These data facilitate understanding of molecular 
pathways underlying desmin-related myopathy development, and increase existing 
knowledge of intracellular interactions within the muscle cell.!!  
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1 INTRODUCTION 
1.1 INTERMEDIATE FILAMENT  
1.1.1 Intermediate filament overview 
The cytoskeleton is composed of three classes of protein filaments—microtubules, 
intermediate filaments, and microfilaments, named after their diameter size: 25 nm, 
10 nm, and 7 nm, respectively. The intermediate filament (IF) protein family is 
usually subdivided into five principal types according to primary amino acid 
sequence, net acidic charge, assembling properties, and tissue expression pattern. 
The types I and II IF comprised of acidic and basic cytokeratins that form only 
heterodimers and are found in epithelial cells. In contrast, the type III IF, 
encompassing vimentin, desmin, glial fibrillary acidic protein (GFAP), and 
peripherin form homodimers and are present in fibroblasts, muscle cells, some 
neural cells. The type IV IF includes low-, middle-, and high-molecular weight (MW) 
neurofilaments, α-internexin, and nestin that are mainly expressed in neural cells. 
Type V IF is constituted of nuclear lamins, considered to stand apart from the other 
types due to the presence of nuclear localization signal in its primary sequence, and 
its ubiquitous expression pattern (Table 1) (1,2). It is important to note that IF of 
different types can co-exist in one cell, e.g. keratin and vimentin in human alveolar 
carcinoma cells (2). Moreover, some of them display ability to co-polymerize, e.g. 
during embryonic development vimentin and desmin co-expressed in early muscle, 
however vimentin is not found in mature muscle cells (3,4).  
1.1.2 Intermediate filament structure and assembling 
Despite the differences in amino acid sequences and expression sites, all IF share 
common tripartite structural traits. IF consist of a central α-helical rod domain 
flanked by non-helical head and tail domains. The rod domain is composed of four α-
helical segments that retain repeating heptad motifs (1A, 1B, 2A, 2B). These 
segments are interrupted by linker sequences (L1, L12, L2). The rod domain is ≈310-
350 amino acid residues in length. This domain governs the process of filament 
dimerization and subsequent formation of coiled-coil structure. 1A and 2B segments 
are considered to be the most conserved part of IF. Whereas 1A is responsible for 
filament assembly, 2B mediates lateral filaments association (5,6). Assembly of IF 
occurs in three stages. During the first stage filament molecules form parallel dimers 
due to the rod domain interactions. Two antiparallel half-staggered dimers assemble 
to form tetramers. Eight tetrameres organize into unit-length filament (ULF) ≈17 nm 
in diameter and ≈60 nm long by means of lateral association. In the second stage 
ULFs undergo longitudinal annealing, resulting in formation of non-compact long 
filaments, ≈17 nm in diameter and hundred nanometers long. In the final assembly 
stage these loosely packed structures reorganize into mature tightly packed 
intermediate filaments ≈10 nm in diameter (Fig. 1) (6,7). It is noteworthy that 
rearrangements cause neither loss of the protein mass nor gain of the protein length 
(8,9). 
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Figure 1. Schematic image of typical intermediate filament structure and process of intermediate 
filaments assembling (adapted from Godsel et al., Trends Cell Biol. 2008 Jan; 18(1): 28–37, (10); 
republished with permission). 
1.1.3 Intermediate filament functions and interaction partners 
For a long time cytoplasmic IF were considered to serve only as structural proteins, 
with a predominant role in maintaining cellular architectural integrity. Since IF were 
isolated as intact filaments and almost did not exist in soluble form, they were 
counted as a static element of the cytoskeleton, in contrast to actin and tubulin 
proteins that depend on pool of soluble subunits (11,12). However, over the past 
decades this conception was greatly revised due to experiments with microinjections 
of exogenous soluble proteins and fluorescent recovery after photobleaching (FRAP) 
analysis (13–16). It was established that exogenous keratin and vimentin freely 
incorporated into endogenous filamentous network via dynamic subunit exchange 
processes (17,18). FRAP analysis confirmed that subunit exchange took place along 
the filament length (16,19,20). Therefore, it was determined that IF are remarkably 
dynamic structures. Moreover, it was demonstrated that dynamic actions are under 
control of numerous molecules, mostly signaling, rather than structural, e.g. kinases 
(21, 22), phospholipases (23), GTPases (24). Subsequently, IF were proposed to be 
engaged in signal transduction processes affecting participants of signaling 
pathways, altering their intracellular localization, hindering or promoting their 
translocation between organelles (25). Besides, IF might interact with the other 
intracellular components, organelles, and molecules by means of linker proteins 
belonging to the plakin family. Plectin is one of the most important members of this 
family since it mediates crosstalk between all cytoskeletal components (26), as well 
as interconnects IF and mitochondria (27). Vimentin was recently showed to 
contribute to the cellular mechanics by providing intracellular stiffness and 
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maintaining spatial content organization (28). Subsequently, other studies unveiled 
role of vimentin also in cell adhesion and migration (23). Nuclear lamins reside in 
nuclear lamina, between the inner nuclear membrane and chromatine. Apart from 
maintaining nuclear structure lamins are also involved in gene expression, 
chromatin organization, cell cycle regulation, embryonic development, and cell 
differentiation (29–31). To sum up, IF are immensely dynamic and interactive 
molecules, accomplishing diverse functions, not limited to structure maintenance.  
1.1.4 Intermediate filament mutations and diseases 
Due to the high variability of IF family members, their functions, and interaction 
partners IF gene mutations often result in severe disorders. The causative role of 
keratin K14 genes mutations in developing epydermolysis bullosa simplex was 
confirmed at the end of the 1980s (18). Keratin aggregates served as a hallmark of 
affected tissues, and were detected in cell culture expressing dominant-negative 
mutant form of the keratin gene (32). Cells devoid of keratin network lost their 
resilience and resistance to mechanical stress—for this reason it was deduced that 
the primary role of keratin filaments is to provide mechanical support of epithelial 
cells. Up to date, mutations in ≈20 keratin genes have been described in connection 
with monogenic diseases. Nevertheless, some of them do not result in a failure of IF 
polymerization process. Detailed examination of these mutations instead revealed 
impairment of pigment uptake and transport mechanisms within keratinocytes (33). 
Type III IF mutations are also linked to clinical phenotypes. Desmin was the first 
non-keratin IF characterized to play a causative role for the development of desmin-
related myopathy (DRM). DRM is a variant of myofibrillar myopathy, featured by the 
presence of desmin-positive aggregates within the cardiac and skeletal muscle cells 
(34–36). Subsequently, non-aggregate as well as aggregate desmin mutations were 
described in patients with cardiac and skeletal myopathies (37), suggesting 
impairment of nanomechanical properties of desmin, rather than structural entirety 
(38). Alexander disease, characterized by white-matter degeneration and the 
formation of astrocytic cytoplasmic inclusions, is caused by mutations in GFAP, 
another member of type III IF. Accumulation of cytoplasmic aggregates containing 
GFAP is demonstrated as histological sign for this illness (39). A number of 
neurodegenerative disorders are now known to be related to mutations in type III 
and IV IF, e.g. amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, 
Parkinson disease. Similar to earlier described phenotypes, these pathologies can be 
identified by the presence of abnormal protein aggregates in neurons and glia of the 
central nervous system. Experimental data revealed that mutations result in 
alteration of neuronal IF expression pattern and biochemical functions (For review 
see 40). Laminopathies is a broad group of diseases associated with mutations in 
LMNA/C gene and commonly affect tissues of mesenchymal origin (41). A wide 
range of clinical phenotypes are linked to nuclear lamin mutations, including 
cardiomyopathies and distal myopathies (42), lipodistrophies (43), progeria (44), 
and mandibuloacral displasia (45). It has been discovered that lamin mutations 
impair cell differentiation processes, probably altering gene expression pattern. 
However, precise molecular mechanisms remain to be elucidated. For some 
mutations aggregates residing within the nuclei have been detected (46). Taken 
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together, despite the majority of IF associated disorders being accompanied by 
accumulation of protein aggregates, development of the disease could not be 
attributed to structural defects only. IF non-mechanical properties, e.g. organelle 
positioning, signaling, cellular transport, gene expression are here plausible factors 
for the pathogenesis process.  
1.2 DESMIN  
1.2.1 Desmin overview 
Desmin is a major IF of cardiac, skeletal, and smooth muscle cells. It was originally 
isolated from chicken smooth muscle, and characterized as a 100Å protein due to its 
size (47). Desmin is a 53 kDa protein expressed in mature muscle cells, and serves as 
an important early marker for myogenic cells (48). Like all myogenic proteins 
desmin expression is under control of basic helix-loop-helix (bHLH) transcription 
factors—MyoD, myogenin, and MRF4 (49). Moreover, desmin can be found in 
undifferentiated satellite cells, however at low levels (50). Along muscle 
development, desmin is upregulated, while vimentin pre-existing in immature 
myoblasts undergoes downregulation. Desmin filaments associate with vimentin 
filaments to form elongated strands. Upon myofiber development, these strands 
rotate transversely to take the position across myofibrils at the level of Z-discs (51). It 
has been demonstrated in vitro that desmin filaments indirectly mediate myoblast 
fusion via interaction with MyoD (52). On the other hand, desmin knockout mice 
displayed normal muscle maturation and were viable, thus disproving the essence of 
desmin in embryogenesis (53). This phenomenon might be accounted for large 
compensatory effect of cytokeratins. In fast twitch skeletal myofibers desmin is co-
expressed with keratins K8 and K19 in the area of Z-discs and M-line, cooperating to 
interconnect neighboring myofibrills (54). Further investigations have broaded 
existing knowledge regarding desmin-keratin relations. To conclude, these data have 
shown that keratins might act independently, complementary or adversely to desmin 
activity (55). 
1.2.2 Desmin functions and interaction partners 
1.2.2.1 Desmin localization 
Desmin filaments are mainly localized in the area of Z-discs, under the sarcolemma 
at the myotendinous and neuromuscular junctions in skeletal muscle cells. Desmin is 
found at intercalated discs and Purkinje fibers in cardiac muscle (Fig. 2). Desmin 
filaments interconnect Z-discs to each other and to the sarcolemma at the level of 
costameres, thus integrating the process of muscle contraction (56). 
1.2.2.2 Desmin functions and interaction partners 
It is noteworthy that a bulk of existing data about desmin functions and interaction 
partners were obtained from demin knockout mouse model (57). As was stated 
before, desmin ablation did not effect the muscle development, and knockout 
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animals were viable and fertile. At the same time, mice lacking desmin displayed 
multisystem disorders involving all muscle types. Analysis of affected tissues 
revealed severe disruption of cell architecture and massive degeneration of tissue, 
especially in the myocardium. Cardiomyocytes underwent progressive 
degeneration and calcification. On the structural level lateral alignment of 
myofibrils was missed and mitochondrial organization was disrupted (57). 
Therefore, the desmin knockout mouse model verified that desmin expression is 
pivotal for maintaining structural integrity of striated muscles. Thereafter, these null 
mice were studied to assess desmin impact on physiological properties of myofibrills. 
The absence of desmin resulted in more rapid fatigue and less isometric force. 
Myofibrillogenesis during regeneration was abnormal, and displayed signs of 
disorganization. However, vimentin was not upregulated. It is remarkable that in 
desmin-null mice weight-bearing muscles, e.g. soleus, or continually used muscles, 
e.g. diaphragm or myocardium, were mostly affected (53). Recently, elevated levels 
of inflammation response and muscle regenerative processes, as well as adipocyte 
infiltration were reported for the desmin deficient muscles responding to notexin 
treatment (58). To expand the previously obtained knowledge the desmin knockout 
model was used to estimate the effect of desmin on mitochondrial spatial 
orientation and bioenergetic functions. It was disclosed that desmin filaments play 
a key role in mitochondrial anchoring within the myofibers. Slow twitch skeletal 
myocytes lacking desmin filaments demonstrated aberrant accumulation of 
mitochondria in the subsarcolemmal space, while cardiomyocytes demonstrated 
additional extensive mitochondrial proliferation after work overload. To estimate 
mitochondrial activity ADP-stimulated respiration was measured in situ and in 
isolated mitochondria. Interestingly, isolated mitochondria did not show any 
differences in respiration rates between knockout and wild-type (WT) animals, in 
contrast to in situ measurement, where desmin-null myocardium and soleus 
muscle exhibited reduced ADP-stimulated oxygen consumption rate (59). Thus, it 
was concluded that desmin affects not only mitochondrial positioning, but also 
mitochondrial functional properties. Subsequently, it was found that plectin, a 
member of cytolinker proteins, provides a desmin–mitochondria link (27). Later 
on, desmin deficient muscles were tested for response to isometric exercise and to 
susceptibility to mechanical injury. Desmin knockout muscles were shown to 
generate lower force and be less exposed to injury in comparison to WT muscles 
(60). These data demonstrate that lack of desmin IF reduces isometric force 
production, and that the desmin knockout muscle is less vulnerable to mechanical 
injury. Very recently desmin was found to be involved in mechanical response to 
high isometric stress by modifying the nuclei shape, and by participating in stress-
mediated JNK signaling within myofibers (61). Altogether, desmin filaments 
similar to other IF execute interactions with signaling proteins, cytolinkers, 
shaperones, components of cytoskeleton (62,63), and various membranous 
organelles, e.g. nucleus (61,64), mitochondria (59), lysosomes (65), and probably 
sarcoplasmic reticulum (66,67). Therefore, like other IF, desmin provides cellular 
integrity, supports crosslinks between structural and signaling proteins, maintains 
spatial localization of cellular organelles, and participates in mechanotransduction 
of extracellular stimuli. Desmin and its counterparts establish a cellular scaffold for 
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adjusting mechanochemical signaling and trafficking processes within the cell, thus 
controlling cell fate. However, the precise molecular machinery underlying most of 
this networking remains to be elucidated. 
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  Table 1. Types of intermediate filaments and associated diseases. 
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1.2.3 Desmin gene and mutations 
1.2.3.1  Desmin gene 
Nucleotide sequence of the human desmin coding gene (DES) was deciphered in 
1989 by Li et al. (72). It was determined that DES is a single copy gene that spans a 
region of 8.4 kb and encompass nine exons separated by introns. DES has one 2.2 kb 
mRNA transcript found in all types of muscle cells (72). Further investigations 
allowed to perform gene mapping and to assign DES to 2q35 band in the human 
karyotype (73). In accordance with its protein structure, the DES gene coding 
sequence might be organized in three domains corresponding to non-helical head 
and tail domains, and α-helical rod domain. The latter, the α-helical core, is the most 
conserved, and is composed of four segments—1A, 1B, 2A, 2B, maintaining heptad 
repeats of hydrophobic and hydrophilic amino acids. These repeats drive the 
formation of desmin dimers (74). Detailed structural analysis of the rod domain 
unveiled the presence of so-called «stutter» element in the sequence of 2B segment, 
which is equivalent to the deletion of three amino acids residues, and «stammer» 
corresponding the deletion of four amino acids residues (75). Further, it was 
convincingly proved that «stutter» is an obigatory trait of all IF and its position is 
strictly defined. Moreover, addition of the missed three amino acids to the «stutter» 
sequence had a deleterious effect on the filament polymerization process (5). Thus, it 
was concluded that «stutter» elements control desmin IF assembly. Another 
structural sequence found in 2B segment is 405-YRKLLEGEESRI-416 motif. This 
element is responsible for the coiled-coil untwisting and serves as starting point to α-
helices dissociating from each other (76). Non-helical head and tail domains are 
mainly composed of β-sheets, while the latter displays mostly random structure (77), 
and plays a distinct role in the regulation of ULF width during tetrameres formation 
(78). Furthermore, the tail domain was discovered to interact with other components 
of the cytoskeleton (79). In conclusion, all structural elements of desmin participate 
in processes crucial for protein organization and functioning.  
1.2.3.2 Desmin mutations  
Up to date, nearly 70 DES mutations have been described in patients with affected 
cardiac and skeletal muscles (Fig. 3a). In general, DES mutations display autosomal 
dominant (AD) inheritance pattern accompanied with intracellular aggregate 
formation (80). Three families with autosomal recessive (AR) inheritance with 
either homozygous or compound heterozygous DES mutations have been described 
(81–83). De novo DES mutations have also been reported (84–86). The most 
frequent are missense DES mutations resulting in amino acid substitution (87). In 
some families with AR inheritance a small in-frame deletion leading to 
p.Arg173_Glu179del has been described (81,83). In other families larger deletion of 
22 bp in exon 6 resulted in occurrence of premature stop codon and a complete lack 
of desmin has been reported (88). A series of mutations impairing splicing process 
have also been identified, for instance deletion of exon 3 splice sites resulted in 
complete ablation of 96 bp region corresponding to exon 3 (89). An insertion of a 
single nucleotide resulted in premature termination of translation process (90). 
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Some DES mutations are less pathogeniс than others, and appear often to depend on 
localization site of the mutation. Comparative analysis of the pathogenic potential of 
various DES mutations unraveled that mutations residing in 2B segment of the rod 
domain exerted more severe effect on filaments architecture in contrast to tail 
domain mutations (91). In addition, previous studies indicated a phenomenon of 
incomplete penetrance for tail mutation I451M. In a family carrying this mutation, 
only a subset of carriers developed a cardiac phenotype (92). Later on, in another 
family with progressive skeletal myopathy there were no evidence of cardiac 
involvement for three members carrying the I451M mutation (93). Recently, it was 
discovered that rare DES single nucleotide polymorphism (SNP) result in only mild 
alterations in filament structure during development of skeletal and cardiac muscle 
disorders (38). Based on these data it can be concluded that DES rearrangements 
play a causative role in development of striated muscle disorders. The extent of its 
negative effect depends on the type of rearrangement as well as the site of its 
localization. 
1.3 DESMIN-RELATED MYOPATHY 
1.3.1 Desmin-related myopathy overview 
The term myofibrillar myopathy (MFM) was first introduced in 1996 by Nakano et al. 
to cover a number of various non-inflammatory pathological muscle conditions 
specified by common denominators—abnormal foci of desmin positivity, focal 
dissolution of myofibrils, accumulation of myofibrillar degradation products, and 
ectopic expression of multiple proteins in the abnormal fiber regions (94,95). A 
skeletal muscle biopsy is always utilized to establish the diagnosis of MFM. Electron 
microscopy shows disintegration of myofibrils starting from the Z-disc. Gomori 
trichrome staining indicates the presence of a mixture of amorphous, granular or 
hyaline deposits in abnormal myofibers. Immunohistochemical studies discover 
focal accumulation of desmin, αB-crystallin, dystrophin, and myotilin in abnormal 
muscle fibers. Typical histological features include focal areas with reduction or total 
loss of ATPase and oxidative enzyme activity in irregular fiber areas (96). Desmin-
related myopathy (DRM) (OMIM 601419) has been described as a distinct subtype of 
MFM, characterized by intracytoplasmic accumulation of desmin-positive deposits 
in striated muscle cells (97–101). However, initial investigations regarding the 
genetic nature of DRM did not attest involvement of DES mutations in development 
of this disorder (102). Only later, a number of clinical cases have been reported 
confirming a role of DES in DRM evolvement (34,82,81,103). Since then, many new 
affected families have been identified. Novel data provide a more detailed analysis of 
clinical manifestation and pathogenesis of DRM.  
1.3.2 Desmin-related myopathy clinical manifestation 
At the present time a key limitation of studying DRM incidence and prevalence is the 
lack of epidemiological data. As discussed by Clemen et al. (87) DRM belongs to a 
class of rare diseases with no more than 5 affected in 10000 individuals. Much 
research on DRM epidemiology has been done in meta-analysis study encompassing 
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159 cases with 40 different DES mutations (36). DRM was reported in diverse ethnic 
groups and affected both males and females. A gender impact on DRM incidence was 
clearly shown by two studies, where males suffered from sudden death of cardiac 
origin, while females exhibited a more benign myopathy of distal onset and slower 
progression (36,104). The time of the first disease onset is wide ranging from the 1st 
up to 8th life decades, with more frequent cases in the period from 2nd up to 4th 
decades. Disease manifestation in the 1st decade was emanated by rare recessive 
mutant desmin forms (82,83,88,99). A meta-analysis described that more than 70% 
of patients exhibited myopathy or muscular weakness, with elevated plasma creatine 
kinase levels in more than 60% of the cases. Among these patients 67% have 
combined distal and proximal muscular weakness, while isolated distal weakness 
was found in 27% and isolated proximal weakness in 6%. The distal muscle weakness 
generally precedes the proximal muscle impairment with muscle weakness in lower 
and upper limbs. Muscle weakness can progress to trunkal, neck, and facial muscles. 
A combination of signs of striated muscle pathologies was found in 49%. 
Neurological symptoms were found in 74% and cardiological symptoms in 74% of 
patients, while both neurological and cardiological symptoms presented in 49% of 
subjects, isolated neurological signs in 22%, and isolated cardiological signs in 22%. 
Up to 50% of carriers had cardiomyopathy and around 60% had cardiac conduction 
disease or arrhythmias, with atrioventricular block as a definitive indicator. 
Respiratory insufficiency was presumed in 26% of carriers, since death was reported 
in 26% of carriers at a mean age of 49 years. Sudden cardiac death was recorded for 7 
patients. Five patients harboring DES mutations did not show any clinical phenotype 
(36). According to this meta-analysis, DRM is a heterogenous group of disorders 
with greatly varying clinical phenotypes with predominance of skeletal and cardiac 
muscle involvement, at times clinical forms can overlap (Fig. 3b, 3c). 
1.3.2.1 Skeletal muscle involvement in desmin-related myopathy 
Initially DRM was associated with progressive skeletal myopathy, mostly affecting 
distal extremities, and especially legs. Subsequently, DES mutations were shown to 
be cosegregated with scapuloperoneal distal myopathy (105), limb girdle myopathy 
(106), and generalized myopathy phenotype (107). In 2007 Fischer et al. addressed 
a question about comparative analysis of affected skeletal muscles in DRM (108). 
They performed a retrospective muscle imaging assessment in a series obtained 
from 19 DRM patients ranging from mild to severe muscle involvement. In all of 
these patients the semitendinosus muscle was at least equally affected as the biceps 
femoris muscle, and the peroneal muscles were similarly involved as the tibialis 
anterior. More detailed analysis revealed the following muscle characteristics: in 
pelvic muscles—the gluteus maximus muscle was significantly more involved than 
the gluteus medius and minimus muscles; in thigh muscles—semitendinosus, 
sartorius, and gracilis were the most affected muscles exceeding the involvement of 
the adductor magnus, biceps femoris, and semimembranosus; in anterior 
compartment—rectus femoris, vastus lateralis, intermedius, and medialis were 
relatively spared in most patients; in lower legs—the peroneal muscles displayed 
significantly more lipomatous changes than the tibialis anterior and muscles of the 
posterior compartment (soleus, medial, and lateral gastrocnemius). Distal muscle 
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involvement was slightly increased in comparison to proximal muscles (thigh and 
pelvis) (108).  
 
Figure 2. Schematic representation of the desmin filaments scaffold with its direct and indirect 
interaction partners in (a) cardiomyocyte and in (b) cardiomyocyte harboring mutant form of 
desmin (adapted from Capetanaki et al., Current Opinion in Cell Biology. 2015; 32:113–120, (109); 
republished with permission). 
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Figure 3. Desmin mutations and pathophysiology of desmin-related myopathies (a) schematic 
representation of described mutations. Mutations are subdivided into three groups depending on 
related phenotype: skeletal (blue), cardiac (red), both skeletal and cardiac (purple); (b) the major 
phenotypes associated with mutations—distal myopathy and cardiomyopathy; (c) meta-analysis of 
159 patients with desmin-related myopathy. Dilated (DCM), restrictive (RCM), hypertrophic 
(HCM), arrhythmogenic right ventricular (ARVC) cardiomyopathies (adapted from Hnia K. et al., 
Cell Tissue Res. 2015; 360:591–608, (110); republished with permission). 
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1.3.2.2 Cardiac muscle involvement in desmin-related myopathy 
Cardiac muscle involvement in DRM can precede, coincide or succeed skeletal 
myopathy (103). Some cases have also been reported with isolated cardiac 
phenotype, namely dilated cardiomyopathy, without affecting skeletal muscles 
(92,111). Cardiac disease manifestation comprise all forms of cardiomyopathies—
dilated (111), restrictive (112), hypertrophic (89), and arrhythmogenic right 
ventricular cardiomyopathy (113), as well as cardiac conduction disease (34,85,114) 
with atrioventricular block (89). The earlier mentioned meta-study revealed that 
74% of all DRM patients developed a cardiomyopathy. The dilated form of 
cardiomyopathy was observed in 17%, hypertrophic cardiomyopathy in 12%, 
restrictive cardiomyopathy in 6%, and arrhythmogenic right ventricular 
cardiomyopathy in 1% of the patients. Cardiac conduction defects were observed in 
62% of patients, while two thirds of them displayed cardiomyopathy as well. 
Atrioventricular block was the most frequent manifestation of cardiac conduction 
defects—almost 50% usually requires pacemaker implantation (36). 
1.3.2.3 Other muscle involvement in desmin-related myopathy 
Apart from skeletal and cardiac muscle engagement, respiratory muscle weakness 
was reported in 26% of analyzed patients, being the leading reason of patient’s death 
(36). Several evidence of smooth muscle involvement were uncovered by Ariza et 
al., who showed intestinal pseudo-obstruction (99), Goldfarb et al. demonstrated 
swallowing insufficiency (82), and Olive et al. described nuclear and cortical 
cataracts (115). 
1.3.3 Desmin-related myopathy pathogenesis 
1.3.3.1 Cellular alterations 
Pathological changes of genetically proven DRM include the presence of 
intermyofibrillar, subsarcolemmal or perinuclear desmin-positive aggregates both in 
skeletal and cardiac muscles, additionally in myocytes Z-disc streaming resulting in 
loss of tension transmission between sarcomeres (116). Analysis of patients skeletal 
muscle biopsies exhibited irregular shape of muscle fibers and abnormal 
mitochondrial enzyme staining (90,117). Cardiomyocyte hypertrophy and disarray, 
accompanied with misshaped nuclei and degenerating mitochondria were 
described in desmin deficient mice (118,119). Overall, it is considered that the 
severity of muscle pathophysiological changes reflects the DRM stage. The 
following approaches are commonly used to verify the presence of myopathological 
alterations: light microscopy, immunostaining, and electron microscopy. 
Histological analyses of muscle biopsies have shown a myopathic pattern with 
rounding of muscle fibers, increased fiber size, abundance of necrotic and 
regenerating fibers, internalization of nuclei, and an increase of connective tissue 
content (For review see 87). In addition, haematoxylin-eosin and Gomori 
trichrome staining revealed multiple fibers with cytoplasmic and subsarcolemmal 
basophilic inclusions (101,120). Analysis of succinate dehydrogenase and 
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cytochrome c oxidase expression demonstrated multiple muscle fibers with focal 
areas of attenuated or devoid of enzyme expression indicating a focal depletion of 
mitochondria (106). Another study demonstrated a vacuolar myopathy with single 
or multiple round or rimmed vacuoles. The majority of these vacuoles contained 
PAS-positive material. Multiple fibers displayed dots of increased acid phosphatase 
reactivity within the cytoplasm and partially at the rim of larger vacuoles. In 
addition to membrane- and non-membrane-bound vacuoles, the ultrastructural 
analysis revealed multiple fibers containing granulofilamentous material (107). It 
was also shown that «rubbed-out» fibers were more numerous in DRM than in 
other types of MFM (121). Desmin immunostaining is performed as a diagnostic 
tool to illustrate protein inclusions in subsarcolemmal or sarcoplasmic regions. 
However, these inclusions also exhibit immunoreactivity to other miscellaneous 
cytoskeletal and signaling proteins. For instance, αβ-crystallin (90), filamin-C 
(122), and myotilin (123) positive staining is seen in aggregates in DRM as well as 
in other form of MFM (120,124). Electron microscopy discovered accumulation of 
granulofilamentous material in the subsarcolemmal space and between 
neighboring myofibrils, as well as cytoplasmic bodies and autophagic vacuoles 
(125,126). These intracellular changes were concomitant with structural Z-disc 
alterations—streaming, irregularities, and total loss of structure (125). Typical signs 
of accompanying mitochondrial pathology with normal or abnormal morphology 
were their accumulation in the subsarcolemmal area, or depletion of mitochondria 
(116). 
1.3.3.2 Phenotype-genotype correlation 
As was previously discussed, mutations in DES are the leading genetic cause of DRM 
development. Since the beginning of 2000s due to the genetic testing achievements 
it became possible to link clinical phenotypes and different DES mutations. 
Numerous original studies and reviews summarize available data regarding 
phenotype-genotype correlations (35,36,80,87,93,111,115,127). Mutations have been 
found in all DES domains—non-helical head and tail domains, as well as in all 
segments of the α-helical rod domain, where the majority of mutations affect the 2B 
segment. According to meta-analysis data mutations in 2B segment are more 
prevalent in patients with skeletal myopathy (in conjunction with or without cardiac 
involvement), whereas mutations in head and tail domains were found in patients 
with isolated cardiological or combined phenotypes (36). I451M is among the first-
described tail mutations leading specifically to dilated cardiomyopathy without any 
skeletal muscle phenotype. Some carriers of the I451M mutation did not develop 
any phenotype, implying incomplete penetrance (92,93). Further studies of DES 
variants underlying dilated cardiomyopathy disclosed that disease-causing 
mutations can reside out of the tail domain, as demonstrated by mutation in the 
highly conserved segment of the 1A rod domain (111). It is important to note the 
study from 2008 by Strach et al. arguing the concept of phenotype-genotype 
correlations. Eleven patients with heterozygous E245D, D339Y, R350P and L377P 
DES mutations corresponding to the rod domain without cardiac symptoms were 
reported. Clinical evaluation revealed a marked variability of skeletal, respiratory, 
and cardiac muscle involvement between patients harboring identical mutations, 
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ranging from asymptomatic to severely deteriorated. Therefore, the authors 
concluded an absence of distinct genotype-phenotype correlations in patients with 
genetically proven DRM (127). 
1.3.3.3 Mechanism of DES mutation action 
Aggregate toxic effect 
DES A337P and A360P were the first described missence mutations associated with 
familial cardiac and skeletal myopathy (82). Thirteen of up to date described DES 
mutations introduce the amino acid proline (110). Proline normally does not 
present in the desmin amino acid sequence, since it can act as a potent helix 
breaker (128). Forced introduction of proline in desmin leads to disturbance of 
polymerization resulting in formation of short, thick, and kinked abnormally-
assembled filaments in vitro (129). Functional analysis has been performed for a 
DES homozygous deletion of 21 nt found in a patient with severe generalized 
myopathy (81). This study provided evidence of greatly affected assembly process 
in vivo and in vitro in the presence of this deletion. Filaments totally lost their 
ability to assemble in vitro, while in vivo short rodlets of irregular diameter were 
observed and tended to form aggregates (81). Since then, every year new DES 
mutations have been reported in conjunction with DRM, thus it was crucial to 
identify the precise molecular mechanisms of DES mutations action. Bär et al. 
presented one of the first comparative investigations of α-helical rod domain 
mutations impact on the recombinant protein assembly in vitro and the filament-
forming capacity of IF-free cells transfected with DES cDNA (130). It was 
demonstrated that DES rod domain mutations could violate filament assembly in 
vitro at diverse stages. Mutations associated with the same disease phenotype, 
nevertheless showed different abilities to form filaments—from non-affected to 
severely compromised. Moreover, it was demonstrated that the assembly process 
could be interrupted at almost all stages: tetramer formation, ULF formation, 
filament elongation, and filament maturation. According to their assembly 
properties, mutants behave within the transfected IF-free cells: variants disabling 
to polymerize in vitro presented as dot-like aggregates in the cell cytoplasm (130). 
Further analysis was dedicated to describe the performance of these mutations in 
different cell types, IF-free and expressing vimentin (131). A great variability in 
mutation action was discovered. In vitro filaments-forming mutants were able to 
assemble into filamentous network in cells lacking IF, as well as integrate in pre-
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polymerize in vitro caused destruction of vimentin network prompting its 
aggregation in perinuclear space. Exogenous desmin in these cells was completely 
sequestered from vimentin filaments (131). Subsequent work by Bär et al. was 
focused on biophysical properties of mutant desmin proteins (132). Mechanistic 
details of how mutations affect the filament assembly process were measured by 
employing analytical ultracentrifugation, quantitative scanning transmission 
electron microscopy, and viscometric studies. It was shown that the soluble 
assembly intermediates of the mutant proteins exhibit unusually high s-values, 
compatible with octamers. Several of the filament-forming mutant variants 
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concluded an absence of distinct genotype-phenotype correlations in patients with 
genetically proven DRM (127). 
1.3.3.3 Mechanism of DES mutation action 
Aggregate toxic effect 
DES A337P and A360P were the first described missence mutations associated with 
familial cardiac and skeletal myopathy (82). Thirteen of up to date described DES 
mutations introduce the amino acid proline (110). Proline normally does not 
present in the desmin amino acid sequence, since it can act as a potent helix 
breaker (128). Forced introduction of proline in desmin leads to disturbance of 
polymerization resulting in formation of short, thick, and kinked abnormally-
assembled filaments in vitro (129). Functional analysis has been performed for a 
DES homozygous deletion of 21 nt found in a patient with severe generalized 
myopathy (81). This study provided evidence of greatly affected assembly process 
in vivo and in vitro in the presence of this deletion. Filaments totally lost their 
ability to assemble in vitro, while in vivo short rodlets of irregular diameter were 
observed and tended to form aggregates (81). Since then, every year new DES 
mutations have been reported in conjunction with DRM, thus it was crucial to 
identify the precise molecular mechanisms of DES mutations action. Bär et al. 
presented one of the first comparative investigations of α-helical rod domain 
mutations impact on the recombinant protein assembly in vitro and the filament-
forming capacity of IF-free cells transfected with DES cDNA (130). It was 
demonstrated that DES rod domain mutations could violate filament assembly in 
vitro at diverse stages. Mutations associated with the same disease phenotype, 
nevertheless showed different abilities to form filaments—from non-affected to 
severely compromised. Moreover, it was demonstrated that the assembly process 
could be interrupted at almost all stages: tetramer formation, ULF formation, 
filament elongation, and filament maturation. According to their assembly 
properties, mutants behave within the transfected IF-free cells: variants disabling 
to polymerize in vitro presented as dot-like aggregates in the cell cytoplasm (130). 
Further analysis was dedicated to describe the performance of these mutations in 
different cell types, IF-free and expressing vimentin (131). A great variability in 
mutation action was discovered. In vitro filaments-forming mutants were able to 
assemble into filamentous network in cells lacking IF, as well as integrate in pre-
existing vimentin network in vimentin-positive cells. Mutants that failed to 
polymerize in vitro caused destruction of vimentin network prompting its 
aggregation in perinuclear space. Exogenous desmin in these cells was completely 
sequestered from vimentin filaments (131). Subsequent work by Bär et al. was 
focused on biophysical properties of mutant desmin proteins (132). Mechanistic 
details of how mutations affect the filament assembly process were measured by 
employing analytical ultracentrifugation, quantitative scanning transmission 
electron microscopy, and viscometric studies. It was shown that the soluble 
assembly intermediates of the mutant proteins exhibit unusually high s-values, 
compatible with octamers. Several of the filament-forming mutant variants 
   15 
deviated considerably from WT desmin with respect to their filament diameters 
and mass-per-length values. In the heteropolymeric combination with WT desmin 
four of the mutant variants caused a prominent «hyper-assembly» assessed by 
viscometry. These results indicate that the various mutations found mostly in the 
2B segment of the rod domain may cause distortion of filament formation by the 
mutant protein at distinct stages, and that some of them preclude the assembly of 
WT desmin (132). On the other hand, it has been explicitly demonstrated that 
mutations residing in the 1B segment of rod domain, DES A213V and E245D, form 
filaments in vitro (130). Transfected in IF-free cells these mutants were able to 
produce filamentous network similar to WT desmin. In vimentin expressing cells 
mutants integrated to pre-existed vimentin filaments. Comparable results were 
obtained for DES N393I and D399Y mutations, resided in the area closed to the tail 
region (131). Therefore, desmin aggregate formation cannot be attributed as the 
only reason promoting the DRM development. It is here more reasonable to 
propose the concept of loss of desmin function, rather than gain of aggregates toxic 
function. Data obtained on desmin deficient mouse model also favour this 
perception. Mice completely lacking desmin still developed skeletal and cardiac 
myopathies (57,118,119). It is thus important to focus on desmin functions and 
interactions that might be perturbed due to the loss of proper desmin filament 
structure.  
Nanomechanical property distortion 
One of the first functional studies of desmin in DES knockout mouse unveiled its 
role in the force transmission (53). Moreover, desmin filament elasticity was later 
confirmed in experiments with atomic force microscope approach (133). One year 
later, the same group corresponded another study about IF viscoelastic properties, 
where they demonstrated that IF exhibit a very pronounced increase in elastic 
properties or «stiffness» upon increases in shear stress, a phenomenon referred to 
as «strain hardening» or «strain stiffening» (134). Skeletal and cardiac muscle cells 
constantly undergo mechanical stress due to their contraction ability, while desmin 
filaments participate in cell protection against this stress. Mutations in 2B segment 
tail end, namely DES Q389P and D399Y, previously reported to be filaments 
assembly-competent (130,131), were investigated by aforementioned atomic force 
microscope approach (135). Despite the presence of virtually regular filament 
network, local variations in tensile properties along the filament length were 
exhibited in comparison to WT. From this fact the authors concluded that DES 
Q389P and D399Y may cause muscle disease by altering particular biophysical 
properties of the desmin filaments and compromising their nanomechanical 
properties (135). Tail DES mutations exhibited a decrease in «strain stiffening» 
compared to DES WT and promoted non-affine network deformation, thus 
significantly modifying the response to applied load (136). Another confirmation of 
DES mutations impact on cells vulnerability to mechanical stress was obtained on 
the culture of myoblasts isolated from a patient carrying DES R350P. Compared to 
WT cells, these myoblasts demonstrated increased contractile prestress and were 
more susceptible to stretch-induced programmed cell death, implying a higher 
baseline stiffness (137). To sum up, mechanotransduction properties of the muscle 
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cells are ensured by desmin filaments, while the expression of mutant desmin 
contributes to an increased biomechanical cell vulnerability. Increased 
vulnerability of muscle fibers in response to shear or pulling force during 
contraction-relaxation cycles has been reported as a central mechanism for muscle 
fiber degeneration (8).  
Violation of desmin-protein interaction 
Intracellular protein aggregates are considered as a molecular hallmark to diagnose 
DRM. Immunostaining analysis revealed that desmin is not the only component of 
aggregates (90,120–124). High-throughput proteomic approach was applied to 
describe protein content of aggregates found in patients with DRM (138). Various 
structural and signaling proteins showed to be over-represented in aggregates, thus 
confirming their direct or indirect links with desmin filaments, e.g. αβ-crystallin, 
synemin, syncoilin, nestin, plectin, filamin C, myotilin, dystrophin, utrophin, 
dystroglycans, sarcoglycans, caveolin, dysferlin, actin, actinin, N-CAM, NOS, 
collagen VI, laminin, b-spectrin, and ubiquitin. The majority of these proteins were 
described as an aggregate component for the first time by Maerkens et al. in 2013 
(138). Some of these proteins are known to be localized in the Z-disc area, thus 
supporting the Z-disc involvement in desminopathy pathogenesis. However, not 
only aggregate formation disarranges desmin-protein interactions. Two non-
aggregate DES mutations resided in coil 1B segment of the rod domain were 
reported to play a causative role in impairment of desmin-nebulin interaction, and 
destabilizing actin filaments (139,140). Myocytes expressing exogenous DES 
E245D displayed presence of abnormal actin filaments. Detailed analysis 
uncovered that actin filament polymerization is under control of nebulin, a Z-disc 
protein directly linked to the 1B desmin region. Thus, DES E245D mutation 
negatively affects microfilament architecture (139). Another mutation DES K190A 
was also accompanied with irregular actin filamentous network, confirming that 
actin organization is dependent on desmin-nebulin crosslink. These data are in line 
with the perception of desmin being a Z-disc stabilizer, which provides steadiness 
during myocytes contraction (140). Taken together, desmin possesses numerious 
interaction partners; the majority of them are located in the Z-disc. Therefore, 
collapse of desmin filaments regardless presence of aggregates affects the whole 
communication network, thus confirming desmin implication in DRM 
pathogenesis. 
Mitochondrial dysfunction 
The first observations of desmin-mitochondrial crosstalk were obtained on DES 
knockout model. Electron microscopy of cardiac muscles from desmin deficient 
mice showed highly disorganized mitochondria and swollen mitochondrial matrix 
(57). A following study was aimed to assess mitochondrial distribution and 
functional activity in skeletal and cardiac muscles lacking desmin (59). Slow twitch 
skeletal muscle demonstrated abnormal accumulation of mitochondria bundles in 
the subsarcolemmal area, while cardiac muscle additionally displayed extensive 
mitochondria fission in response to work overload. Mitochondrial functional 
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alterations mostly concerned depressed ADP-stimulated respiration. It is of 
interest to note that maximal rates of respiration in isolated cardiac mitochondria 
from desmin-null and WT mice were similar. However, in situ respiration rates 
were significantly reduced in cardiac and slow twitch skeletal muscles lacking 
desmin, whereas fast twitch muscles were unaffected (59). Examination of 
transgenic mouse model expressing low level of the DES L345P discovered 
mitochondrial swelling and vacuolization in muscle from TG mice, as well as 
significant increase in mitochondrial Ca2+ level in skeletal and cardiac myocytes 
during and after contractions (141). To broaden the existing knowledge regarding 
mitochondria in desmin-null cells, investigations of mitochondrial proteome were 
performed (142). Many proteins had a differential expression in WT and desmin 
deficient cells, the majority of which were enzyme subunits. However, cytoskeletal, 
calcium-binding proteins, and others were found as well. Proteome analysis 
unveiled a diversity predominantly in expression of proteins involved in ketone 
body and acetate metabolism, amino-acid metabolism; NADH shuttle proteins, and 
respiratory enzymes; and with less extension in apoptosis, calcium homeostasis, 
and fibrosis (142). The first described cytolinker for IF and mitochondria was 
plectin 1b, a ubiquitously expressed isoform of plectin, capable to tether 
mitochondria with the IF network system (143). Recently, myotubularin was also 
reported to control desmin IF architecture and mitochondrial dynamics in skeletal 
muscle (66). Some assumptions exist that desmin-mitochondrial interactions take 
place in the particular contacting sites rich in the proteins important for 
mitochondrial biogenesis, morphology, and function, e.g. VDAC channels, ANT, 
and the MICOS complex, where mitochondria-sarcoplasmic reticulum cross-talk 
occurs (144). Any distortion of these interactions can affect mitochondrial 
permeability transition pores and mediate apoptosis pathways, thus developing the 
heart pathology observed in DRM animal models (145). Bcl-2 is a well-known 
antiapoptotic protein, which overexpression in desmin-null mice rescued the 
cardiomyopathy phenotype. It was shown that bcl-2 corrected mitochondrial 
defects, reduced fibrotic lesions, and prevented from developing hypertrophic 
cardiac muscle. Overexpression of bcl-2 increased the ability of mitochondria to 
resist calcium exposure, lost due to the desmin absence (146). All of these studies 
indicate that desmin IF play a significant role in mitochondrial positioning and 
respiratory function in striated muscles. Desmin can influence mitochondrial 
function by regulating mitochondrial shape by stretching, and by contraction of the 
mitochondrial membrane, through direct or indirect interactions with 
mitochondrial membrane proteins. Defective mitochondrial homeostasis is a 
common pathological trait found in patients with DRM. 
This section dedicated to putative mechanisms of DES mutations action could be 
much longer, including for instance mutation effect on protein post-translational 
modifications, cell differentiation and development, autophagy and apoptosis 
processes. However, it was limited by the framework of the current thesis and 
covered the issues outlined in this book. 
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1.3.3.4 Animal models to study desmin-related myopathy 
Progress in studying the impact of DES mutations on muscle cell structure and 
functions has been achieved due to the availability of various animal models. 
Desmin knockout mouse model 
DES knockout mouse model was reported independently by two groups in the 
middle of 1990s (53,57). Examination of these animals demonstrated intriguing 
findings. Despite expectations of a more drastic phenotype, desmin-null mice were 
viable and fertile, reproduced normally, and did not show anatomical defects, 
indicating that desmin is not essential for myofibrillogenesis (53). However, the 
desmin-null animals were prone to develop myopathy and cardiomyopathy 
(57,147), and displayed reduced ability to endure chronic and acute bouts of 
running exercise (148). Characterization of electrophysiological cardiac properties 
deciphered that desmin deficiency decreased atrial, but prolonged ventricular 
refractory periods, resulting in ventricular conduction slowing, enhanced 
inducibility of atrial fibrillation, and a reduced susceptibility to ventricular 
arrhythmias (149). The heart function of desmin deficient mice was examined by a 
cardiac MRI study. This demonstrated significantly reduced left and right 
ventricular ejection fractions and cardiac output, an increased left ventricular mass, 
segmental wall thinning, and akinesia (150). Histological analysis of both skeletal 
and cardiac myocytes uncovered the perturbation of myofibrils, Z-disc streaming, 
and subsarcolemmal accumulation of mitochondria. Cardiac tissue examination 
showed areas of fibrosis, ischemia, and calcification (53,57,147). Ultrastructural 
analysis of cardiomyocytes showed increased volume and alterations in intercalated 
disc morphology (118,119). To elucidate molecular pathways underlying 
cardiomyopathy and enhance DES mutant phenotype, DES knockout mice were 
crossbred with transgenic mice, carrying DES mutations. For instance, expression of 
I451M mutation in the desmin-null background helped to describe crucial role of 
head and tail domains in the formation of IF scaffold around Z-discs (151). 
Desmin transgenic mouse model  
Transgenic (TG) mouse models have been used to elucidate the role of particular 
DES mutations in the development of myopathy and cardiomyopathy. The first TG 
mouse model was established in 1996 (152). Chimeric protein composed of desmin 
and vimentin amino acid sequences was expressed under the desmin promoter. 
Despite the low level of expression, this truncated protein had a dominant-negative 
effect on the desmin IF network. Typical loss of cross-striation pattern and 
accumulation of intermyofibrillar deposits were observed in skeletal and cardiac 
samples (152). Next TG model expressing p.Arg173_Glu179del was reported in 
2001 by the group of Jeffrey Robbins and referred as D7-des (153). Examination of 
D7-des TG mouse heart showed aberrant intrasarcoplasmic and electron-dense 
granular filamentous aggregates. The desmin filamentous network was significantly 
distorted, and myofibril alignment was greatly compromised. Systolic function in 
D7-des TG hearts under baseline conditions and during maximal β-adrenergic 
stimulation was significantly reduced (153). These D7-des TG mice were crossed 
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with αβ-crystallin TG mice to amplify the DRM phenotype (154), or with animals 
harboring genes engaged in autophagy (155,156) to characterize this process in 
conjunction with aberrant desmin. Myocardium from double TG exhibited 
significantly more desmin aggregates than from D7-des TG mice. Moreover, double 
TG mice displayed a significantly stronger cardiac hypertrophic response, with the 
mice dying of congestive heart failure before 7 weeks (154). Studies of autophagy 
unraveled that abnormal desmin aggregation impairs the proteolytic function of 
the ubiquitin-protesome system in the heart (155). It was recently shown that 
autophagic flux is increased in desminopathic hearts, since it serves as an adaptive 
response to overexpression of misfolded proteins (156). Our group also established 
DES TG mouse model. The peculiarity of this model was co-expression of 
endogenous DES WT and exogenous DES L345P. Despite the low expression level 
of exogenous DES, reduced contractile function and recovery from fatigue in soleus 
muscle were reported. Moreover, cardiac alterations, particularly a hypertrophic 
left ventricular posterior wall and decreased left ventricular chamber dimension 
were described. Mitochondrial pathology characterized by swelling and 
vacuolization and increased calcium levels were found as well (141). Recently, 
another TG mouse model was reported, namely DES R349P knock-in mice. This 
model recapitulates the characteristics of human missense mutation DES R350P. 
Examination of this model revealed that the distortion of IF network integrity, 
rather than aggregate toxic effect plays a causative role in DRM development (157).  
Zebrafish model 
Over the last 20 years, zebrafish have become a trendy animal model. The first 
paper describing desmin spatial distribution during zebrafish embryonic 
development revealed its concentration at Z-bands and intercalated discs (158), 
while analysis of adult organisms sharply localized desmin to the Z-bands of 
myofibrils (159). Desmin in zebrafish is encoded by two genes, desma and desmb, 
sharing 68.7% and 72.0% similarity with the human desmin protein respectively 
(160). Knockdown of desma via morpholino antisense oligonucleotide approach 
exhibited alteration of Z-disc structure, as well as reduced content of sarcomeres 
for both skeletal and cardiac muscle (161). A recent study reported simultaneous 
knockdown of desma and desmb that resulted in muscle disorganization, reduction 
of larvae size, and declining in fish swimming activity (162). The cardiac phenotype 
has not been studied so far due to the unavailability of fish model possessing DRM 
phenotype with aggregate accumulation.  
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myofibrils (159). Desmin in zebrafish is encoded by two genes, desma and desmb, 
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for both skeletal and cardiac muscle (161). A recent study reported simultaneous 
knockdown of desma and desmb that resulted in muscle disorganization, reduction 
of larvae size, and declining in fish swimming activity (162). The cardiac phenotype 
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2 AIMS OF THE STUDY 
The general aim of the present PhD project was to extend existing knowledge about 
the molecular machinery on how desmin gene mutations lead to the development of 
desmin-related myopathy, with an emphasis on development of cardiomyopathies. 
To address this general aim several specific research questions were stated: 
1. To perform genetic study of a group of patients with cardiomyopathies in 
order to describe novel mutations in the desmin gene and to assess the 
frequency of DES A213V. 
2. To perform genetic study using next-generation sequencing approach of a 
group of patients with idiopathic restrictive cardiomyopathy in order to 
describe novel genetic variants associated with disorder. 
3. To perform functional study of aggregate-prone and non-aggregate-prone 
desmin gene point mutations and compare their effects on mitochondrial 
properties. 
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3 MATERIALS AND METHODS 
3.1 PATIENT MATERIAL 
Studies were performed according to the Helsinki declaration, and ethical permits 
were obtained from local ethic committees in Stockholm and Saint-Petersburg. All 
patients involved in the study signed written informed consent prior to the 
enrollment.  
Genetic study aimed to search novel DES mutations and assess DES A213V 
frequency involved 108 patients with heart failure and cardiac dilation with signs of 
heart failure and enlarged left ventricle dimensions of various etiologies. Clinical 
data and case history were obtained by direct physical examination and from medical 
records. The control group included 300 healthy donors with the same Caucasian 
background. 
Genetic study by next-generation sequencing (NGS) approach included 24 
individuals with restrictive cardiomyopathy (RCMP) hospitalized or treated in the 
clinic of Federal Almazov Medical Research Centre, St. Petersburg, or Astrid 
Lindgren’s Children Hospital, Karolinska University Hospital, Stockholm. The 
RCMP diagnosis was based on the WHO/International Society and Federation of 
Cardiology Task Force clinical criteria, and classified according to the European 
Society of Cardiology classification of cardiomyopathies. To compare the spectrum of 
genetic variants, six patients with early onset ventricular arrhythmias without 
diastolic dysfunction, ischemic heart disease, or structural cardiac abnormalities 
were examined using the same panel of genes. 
3.2 SEQUENCING OF DESMIN GENE 
3.2.1 Sanger sequencing 
Patient genomic DNA was extracted from peripheral blood by using QiAmp DNA 
Blood Mini Kit (52304, Qiagen, USA). All encoding exons of DES were analyzed. 
Detailed parameters of the PCR reactions are available upon request. After 
amplification, PCR fragments were cleaned with a GeneJET PCR Purification Kit 
(K0702, Thermo Fisher Scientific, USA), and cycle sequencing was performed using 
BigDye® Terminator v3.1 Cycle Sequencing Kit  (Applied biosystems, USA) 
according to the manufacturer’s instructions. Sequence analysis was performed on 
ABI PRISM 3130 genetic analyzer, and the data were interpreted using BioEdit 
sequencing analysis program.  
3.2.2 Restriction fragment length polymorphism 
All found DES A213V substitutions were  confirmed by restriction fragment length 
polymorphisms analysis. DES A213V substitution introduced a restriction site for 
AccBsI,  thus in the presense of substitution the original 384 bp PCR  product 
cleaved to 103+281 bps fragments.  
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3.2.3 Next-generation sequencing 
3.2.3.1 Design of the target gene panel  
A list of cardiomyopathies- and channelopathies-associated genes was compiled 
from the literature covering 108 genes that are either known causes or candidate 
genes for RCMP development. To ensure a comprehensive coverage of the target 
genes, all annotated coding regions were extracted based on genes and tracks data 
from RefSeq, Ensembl, CCDS, Gencode, VEGA, SNP, CytoBand. The resulting target 
region covered 426332 bp and was used as input for SureSelect (Agilent 
Technologies, USA) to design the custom capture-oligonucleotides for in-solution 
target enrichment. Manual optimization was applied to readjust capture 
oligonucleotides in regions with lower capture efficiency. In total, 19956 capture 
probes mapping to 424430 bp were synthesized (BED file with target region is 
available upon request). 
3.2.3.2 Gene enrichment and next-generation sequencing 
For all samples alignment was performed using Burrows-Wheeler Aligner (BWA 
MEM) and called with SNPPET tool (http://www.eposters.net/pdfs/snppet-a-fast-
and-sensitive-algorithm-for-variant-detection-and-confirmation-from-targeted.pdf) 
as a part of SureCall software (Agilent Technologies, USA). As an alternative, output 
BAM files obtained from BWA was processed using GATK (V.3.3-
0) http://www.broadinstitute.org/) pipeline to increase reliability. BAM files were 
sorted and indexed with Picard tools (V.1.128) (http://broadinstitute.github.io). 
Restriction enzyme fingerprints was clipped with GATK ClipReads, then BAM files 
were realigned and recalibrated versus dbSNP 138 (NCBI) with GATK tools. 
Coverage metrics files were produced with SAMtools depth and analyzed with a 
custom R script. All samples were annotated using Annovar. Sanger sequencing was 
applied to validate results.  
3.2.3.3 Variant classification 
To express the pathogenic role of the identified genetic variants we utilized the 
classification proposed by Haas et al. (163) with modifications. All disease-relevant 
and disease-modifying variants were classified as damaging (D) or neutral (N) by 
SNPs&GO (164). 
3.2.3.4 Protein network analysis 
A disease interaction network was generated by manual curation using the CIDeR 
database (165). Text-mining tools such as iHop, Chilibot, and EvidenceFinder were 
used for literature mining of Pubmed abstracts and PMC full text articles 
(164,166,167). Proteins with RCMP mutations were analyzed with regard to their 
physical and regulatory interactions. All interactions from the protein network were 
manually curated and supported by experimental evidence from the scientific 
literature. If available, we used information from cell types that are related to cardiac 
cells. 
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3.3 PRIMARY MAMMALIAN CELL CULTURE 
3.3.1 Muscle fiber isolation 
Young (8–16 weeks old) C57BL/6 male mice were supplied by B&K Universal 
(Sollentuna, Sweden). All studies were approved by Stockholm North Local Animal 
Ethics Committee. Mice were sacrificed by cervical dislocation. Muscles were 
removed and placed in DMEM with 1% penicillin/streptomycin (Gibco, USA). Single 
muscle fibers were isolated from flexor digitorum brevis muscle. Isolated muscles 
were cleaned of the connective tissue and tendons and placed in 2 mL of filtered 
0.3% collagenase I (C0130, Sigma, Germany) dissolved in DMEM (Gibco, USA) 
supplemented with penicillin-streptomycin (Gibco, USA) for 2 h at 37°C. After 
digestion, muscles were washed with DMEM supplemented with 20% FCS (Gibco, 
USA) to remove the residual enzyme. Muscles were gently triturated in 2 mL of 
DMEM supplemented with 20% FCS. After trituration, fiber suspension was 
incubated for 10 min in plastic dishes, which was found to be optional for reduction 
the amount of nonmuscle cells contamination. After the 10 min incubation, the fiber 
suspension was plated on Geltrex-coated (Gibco, USA) glass bottom Petri dishes 
(P35G-0-20-C, Mattek, USA), 500 µL of suspension per one dish. Geltrex was diluted 
in cold DMEM (1:100) and the glass bottoms of the dishes were coated and 
incubated at 37°C for one hour, after which the dish was washed with PBS several 
times to remove excess Geltrex. The fiber suspension was plated on the dish and left 
for 10 min to allow fibers to attach to the glass bottom before the addition of 2 mL of 
incubation media (DMEM supplemented with 20% FCS). The incubation media was 
renewed every two days by replacement of half of the medium. Cells were cultured in 
an incubator at 37°C under a 5% CO2 atmosphere. 
3.3.2 Satellite cell isolation, cultivation and differentiation  
Satellite cells were isolated via two strategies. In the first strategy, satellite cells were 
allowed to branch out of muscle fibers and attach to the dish bottom. In the second 
strategy, satellite cells were isolated as a «pure» culture by enzymatic dissociation of 
muscle fibers (168–170). For the first strategy, muscle fibers were isolated from 
soleus and flexor digitorum brevis muscles by incubation in collagenase and 
subsequent trituration as described above and incubated until the satellite cells 
appeared in the dishes. For the second strategy, satellite cells were isolated 
enzymatically according to the protocol of Yablonka-Reuveni et al. (171) with minor 
changes. In brief, isolated muscles were placed directly into enzyme solution, without 
any additional mechanical disruption with scissors. Digestion was done using 
collagenase type I instead of pronase. Muscle mincing was done using sterile blue 
pipette tips instead of glass Pasteur pipettes or serological pipettes; we did not filter 
the cell suspension through a strainer, since in our hands it decreased cell yields. The 
resultant satellite cells were plated on dishes coated with Geltrex instead of Matrigel. 
Thus, soleus and flexor digitorum brevis muscles were digested for 90 min at 37∘ C in 
2 mL filtered 0.1% collagenase I (C0130, Sigma, Germany). To remove collagenase 
and cell debris after digestion, the cell suspension was centrifuged for 5 min at 400 
×g and the supernatant containing enzyme solution was discarded. To release 
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satellite cells from the fibers the pellet was resuspended in 2.5 mL of washing media 
(DMEM supplemented with 10% horse serum (HS) (Gibco, USA)). After the 
resuspension the fibers were let to settle for 5 min and then the supernatant 
containing satellite cells was replaced to a fresh tube. To increase satellite cells yield 
purity this step was repeated twice. The double-collected supernatant was 
centrifuged for 10 min at 1000 ×g, and the resultant supernatant was discarded and 
the pellet of cells was redissolved in 0.5 mL of proliferation media (DMEM 
supplemented with 20% FCS, 10% HS, and 1% chicken embryo extract (C3999, 
USBiological, USA)). Cells were plated on Geltrex-coated glass bottom petri dishes 
and cultured in proliferation medium until 80% confluence was reached. Fusion of 
some cells without external stimuli (differentiation media) was observed usually after 
7 days of cultivation and served as a reliable indicator, after which we induced 
differentiation. To induce satellite cell differentiation, the proliferation media was 
removed, cells were washed once with prewarmed PBS, and then differentiation 
media was added (DMEM supplemented with 2% HS). The differentiation media 
was renewed every other day by replacement of half of medium. Cells were cultured 
in an incubator at 37°C under a 5% CO2 atmosphere. 
3.4 LENTIVIRAL TRANSDUCTION 
Murine desmin (Des, NM 010043.1) cDNA was cloned into a lentiviral plasmid 
vector pBK RSV. It was amplified via polymerase chain reaction to create restriction 
sites for AscI and SpeI on 5’- and 3’-ends. These sites were used for subsequent 
subcloning in a LVTHM plasmid. Site-directed mutagenesis was performed by 
means of polymerase chain reaction with primers containing the desired mutation. A 
set of plasmids carrying mutated copies of Des was obtained and the following 
mutations were chosen for subsequent functional investigation: Leu345Pro, 
Ala357Pro, Leu370Pro, Asp399Tyr. 
The pLVTHM (20 μg), pMD2G (5 μg), and packaging pCMV-dR8.74psPAX2 (5 μg) 
plasmids were cotransfected into HEK-293T cells by a calcium phosphate method. 
The resultant production of lentivirus was concentrated by an ultracentrifugation 
method (20000 ×g for 2 h at 4°C), resuspended in 1% BSA, and frozen in aliquots at 
-80°C, titered using HEK-293T cells as described previously (172) 
(http://tronolab.epfl.ch/). 
Several different approaches were tested to successfully transduce primary muscle 
fibres. To facilitate transduction, polybrene (Sigma, Germany) at a final 
concentration 8 μg/mL was added to all transduced cells. We used (i) 
nonconcentrated virus and DMEM supplemented with 20% FCS as solution for 
muscle trituration and (ii) nonconcentrated and concentrated viral suspension as 
transduction agent and varied (iii) the incubation time with viruses and (iv) the type 
of plating surface. For satellite cells transduction concentrated viral suspension at 
multiplicity of infection of 20 was added to the cells and incubated for 5 min ahead 
of plating. Sixteen hours after transduction, the culture medium was completely 
replaced with a fresh medium. To assess efficiency of viral transduction viruses 
coding GFP were used in parallel. 
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3.5 IMMUNOFLUORESCENCE 
The myogenic nature of the isolated cells was confirmed by immunocytochemical 
staining. Cells were fixed in 4% paraformaldehyde for 10 min at 4°C and then 
permeabilized with 0.05% Triton X-100 for 5 min. Nonspecific binding was blocked 
by incubation of permeabilized cells in 15% FCS for 30 min. Cells were incubated for 
one hour at room temperature with the following primary antibodies: anti-Desmin 
(D33, DAKO, Denmark), anti-Myosin heavy chain (MAB4470, R&D, USA), anti-
Ryanodine receptor 1 (D4E1, Cell signaling, USA), anti-Mitofusin 2 (ab56889, 
Abcam, USA), anti-Lamin A/C (NCL-LAM-A/C, Novocastra, UK). The secondary 
antibodies conjugated with Alexa Fluor 488 or Alexa Fluor 546 (Molecular Probes, 
USA) were applied for 45 min at room temperature. Nuclei were counterstained with 
DAPI (Molecular Probes, USA). 
3.6 MEASUREMENT OF CELLULAR CALCIUM FLUXES  
3.6.1 Loading cells with calcium indicators 
Calcium indicators were used to measure changes in free calcium within the cell. 
Rhod-2 AM (Molecular Probes, USA) was used to monitor calcium in the 
mitochondrial matrix. Cytoplasmic calcium was monitored using either the 
ratiometric indicator, indo-1 AM (Molecular Probes, USA), or the non-ratiometric 
indicator, fluo-3 AM (Molecular Probes, USA). Cells were incubated for 30 min at 
room temperature with 5 µM rhod-2 AM, 2 µM fluo-3 AM, or 5 µM indo-1 AM, then 
washed for 20 min with Tyrode buffer. Mitochondrial membrane potential was 
monitored with tetra-methyl rhodamine-ethyl ester (TMRE, Molecular Probes, 
USA). 
3.6.2 Stimulation of sarcoplasmic reticulum calcium release and 
laser confocal microscopy.  
Cells were stimulated chemically with 2 mM 2-chloro-m-cresol (CmC, Sigma, 
Germany) or continuously with 1 or 10 ms electrical individual pulses at various 
frequencies (1–100 Hz). 
A BioRad MRC 1024 unit (BioRad Microscopy Division, Hertfordshire, England) 
with a dual Calypso laser (Cobolt, Solna, Sweden) attached to a Nikon Diaphot 200 
inverted microscope was used. In the majority of experiments, a Nikon Plan Apo 20× 
dry lens (N.A. 0.75) was used. The rhod-2 was excited with 531 nm light and the 
emitted light collected through a 585 nm long-pass filter, fluo-3 was excited with 491 
nm light and emitted signal was collected at 515 nm. TMRE was excited with 531 nm 
and the emitted light was collected through a 585 nm filter. Confocal images were 
captured every 7 s and a total of 42 images were obtained for every experimental 
condition. Images were analyzed by means of ImageJ (National Institutes of Health 
[available at http://rsb.info.nih.gov/ij]). The average pixel intensity in an area 
surrounding nuclei was defined as the rhod-2 mitochondrial intensity. Background 
fluorescence was measured in an area free of myotubes. Fluorescence intensity is 
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inverted microscope was used. In the majority of experiments, a Nikon Plan Apo 20× 
dry lens (N.A. 0.75) was used. The rhod-2 was excited with 531 nm light and the 
emitted light collected through a 585 nm long-pass filter, fluo-3 was excited with 491 
nm light and emitted signal was collected at 515 nm. TMRE was excited with 531 nm 
and the emitted light was collected through a 585 nm filter. Confocal images were 
captured every 7 s and a total of 42 images were obtained for every experimental 
condition. Images were analyzed by means of ImageJ (National Institutes of Health 
[available at http://rsb.info.nih.gov/ij]). The average pixel intensity in an area 
surrounding nuclei was defined as the rhod-2 mitochondrial intensity. Background 
fluorescence was measured in an area free of myotubes. Fluorescence intensity is 
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expressed as a ratio, F/F0, where F is the fluorescence intensity after subtraction of 
background at each time point and F0 is the myotube fluorescence with background 
subtracted at the start of the experiment. Changes in F/F0 allowed comparison of 
mitochondrial and cytosolic calcium between different dishes of cells. The 
fluorescence emitted by indo-1 was measured with a system consisting of a xenon 
lamp, a mono-chromator, and two photomultiplier tubes (PTI, Photo Med GmbH, 
Wedel, Germany). Indo-1 was excited with 360 nm and the emitted light was 
measured at two wavelengths, 405 nm and 495 nm. The fluorescence of indo-1 was 
converted to [Ca2+]i using an intracellularly established calibration curve as 
described previously (173,174). 
3.7 WHOLE-CELL PATCH-CLAMP 
Calcium current was recorded in muscle fibers and myotubes using the whole-cell 
patch-clamp technique. Current recordings were performed with an Axopatch 200B 
amplifier and Digidata 1440A AD/DA converter (Molecular Device, USA). Data 
collection and analysis were done using pClamp 10.2 (Molecular Device, USA). Patch 
pipettes (1.5–4 MΩ) were pulled from borosilicate glass capillaries (World Precision 
Instruments, USA) by means of a micropipette puller P-1000 (Sutter Instruments, 
USA). The pipette solution had the following composition (mM): 120 CsCl, 5 MgATP, 
10 EGTA, and 10 HEPES (pH adjusted to 7.4 using CsOH) and the bath solution 
contained the following (mM): 120 TEA-Cl, 10 CsCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES, 
0.001 TTX, and 10 glucose, (pH adjusted to 7.4 using TEA-OH). Calcium current was 
evoked with a series of 200 ms depolarizing steps from -30 to 40 mV with 10 mV 
increments. In order to compare currents in different cells, it was normalized to the 
membrane capacitance. 
3.8 MEASUREMENT OF OXYGEN CONSUMPTION RATE  
The oxygen consumption rate (OCR) was measured using a XF96 Analyzer (Seahorse 
Bioscience, USA) that allows real-time determination of oxygen consumption rates. 
Freshly isolated satellite cells were seeded in 96-well FluxPaks microplate (Seahorse 
Bioscience Inc., USA) at the density of 5,000 cells/well and left to proliferate for 
seven days at 37°C. When cells confluence reached about 80%, differentiation was 
induced for another seven days. Before performing the Seahorse assay, cells were 
incubated for 30 min without CO2 in DMEM (supplemented with 10 mM of 
pyruvate, 10 mM of glucose and 2 mM of L-glutamine, pH was adjusted to 7.3). The 
OCR measurements were taken for 3 min with 3 min mixing and 2 min waiting 
periods under basal conditions and after the addition of following inhibitors: ATP 
synthase inhibitor oligomycin (1 µM); a mitochondrial uncoupler, fluoro-carbonyl 
cyanide phenylhydrazone (FCCP) (1 µM); inhibitors of electron transport chain 
complexes I and III rotenone (1 µM) and antimycin A (1 µM) respectively. Five 
respiratory states were defined: (i) basal OCR, (ii) non-phosphorylating OCR, (iii) 
maximal OCR, (iv) non-mitochondrial OCR, and (v) spare respiratory capacity. After 
measurement of OCR, data were normalized to the level of basal respiration in each 
well.  
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4 RESULTS AND DISCUSSION. PAPERS OVERVIEW 
4.1 PAPER I, PAPER II, AND PAPER III 
The first three papers summarize data obtained after genetic studies of patients with 
cardiomyopathies.  
4.1.1 Paper I: Diagnostic challenge in desmin cardiomyopathy with 
transformation of clinical phenotypes  
In this case-report we described the first case of desmin cardiomyopathy with 
transition from a hypertrophic to a restrictive and dilated phenotype and with the 
disease cause originally mimicking myocarditis due to the pericardial effusion, serum 
troponin elevation, and late gadolinium enhancement shown on MRI. Histological 
examination showed moderate myocardial disarray with cardiomyocyte 
hypertrophy, fragmentation and variation of nuclear morphology, and moderate 
perimyocyte and focal fibrosis. Staining with anti-desmin antibody showed local 
loss of regular cross striation and uneven desmin distribution, with areas of no 
desmin immunoreactivity. Sequencing of the desmin gene showed a splice-site 
mutation (IVS3+1G ->A), which was absent in 300 healthy control subjects. 
4.1.2 Paper II: Desmin A213V substitution represents a rare 
polymorphism but not a mutation and is more prevalent in 
patients with heart dilation of various origins 
Recently A213V desmin gene substitution has been described in seven unrelated 
patients with three different phenotypes; distal skeletal myopathy, restrictive 
cardiomyopathy, and dilated cardiomyopathy (91,175). However, this substitution 
has been found also in a group of healthy donors with a frequency of approximately 
1%, and has also been described in a familial case of dilated cardiomyopathy where 
it did not segregate with the disease phenotype (111). The framework of this paper 
was genetical study of patients with heart dilation due to ischemic heart disease, 
alcoholic cardiomyopathy, or viral myocarditis, and 300 healthy controls in order 
to determine the frequency of DES A213V substitution. In the analyzed patient 
group DES A213V substitution was found in 5 out of 108 cases, corresponding to 
approximately 4.6% (p < 0.035). In the control group DES A213V substitution was 
identified in 3 out of 300 patients, representing a rare SNP with a frequency of 
approximately 1%, which corresponds to the earlier reported frequency. Therefore 
we conclude that DES A213V represents a disease-modifying conditional 
polymorphism, rather than disease-related mutation, and plays a role as a 
predisposing factor resulting in maladaptive heart remodelling in the presence of 
other pathological factors.  
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4.1.3 Paper III: Genetic spectrum of idiopathic restrictive 
cardiomyopathy uncovered by next-generation sequencing 
The aim of this study was to identify the genetic background of idiopathic RCMP 
using high-throughput approach of NGS, and 24 patients with RCMP were included 
in the study. All described genetic modifications were referred to as disease-related 
(mutation) or disease-modifying (SNP) variants. Disease-related variants (n=39) 
were identified in 22 out of 108 studied genes and were found in 21 patients (88%). 
The highest number of variants was found in the TTN gene (n=10). Other identified 
genes with multiple variants were MYH7 (n=4) and MYBPC3 (n=3). Three genes, 
TNNI3, MYOM1, and SYNE2, contained two variants each, and the remaining 16 
disease-related variants were evenly distributed across the rest 16 genes. Thus, 
among of 88% genotype-positive cases, single mutations were detected only in 38% 
of the cases, while 50% of the genotype-positive patients carried two or more 
combined mutations. The most frequent combination included mutations in genes of 
sarcomeric contractile and cytoskeletal proteins (21% of all cases). Disease-
modifying variants were detected across 17 out of 108 studies genes (n=38). The 
highest number of disease-modifying variants was also found in the TTN gene 
(n=16). The spectra of genes displaying disease-related variants and disease-
modifying variants in RCMP differed, sharing only 3 genes. Thus, no disease-
modifying variants were detected in the group of sarcomeric contractile protein or 
mitochondrial protein genes. On the other hand, the number of disease-modifying 
polymorphisms in desmosomal and membrane-associated protein genes was 
significantly higher compared to the group of disease-related mutations. We 
compared the spectrum of all disease-associated genetic variants identified for 
RCMP patients and patients with early onset ventricular arrhythmias without 
diastolic dysfunction or structural cardiac abnormalities to analyze its overlapping. 
For the latter group only one disease-modifying variant with minor allele frequency 
of 0.017% was identified in the non-contractile cytoskeletal protein gene MYOM1, 
while no variants were found in sarcomeric contractile protein genes. Thus, the 
genetic spectrum of RCMP-associated variants does not represent a random 
combination and differs from that of other genetic cardiac disorders. To uncover the 
interaction of gene products affected in RCMP pathogenesis we created a protein 
interaction map with 36 proteins found in this study. Including a further 30 
interlinking proteins the network consists of 66 proteins connected by 124 
interactions. Out of the 124 physical and regulatory interactions described here 38 
and 33 were supported by experiments performed in cardiac and other types of 
muscle cells, respectively. Most proteins of this network belong to one of four 
functional groups: (i) sarcomeric contractile proteins, (ii) mechanosensing Z-disc 
proteins, (iii) nuclear membrane, and (iv) outer mitochondrial membrane proteins. 
Thus, in this paper we underlined the role of cytoskeletal protein genes in RCMP 
development. We conclude that RCMP is often triggered by the deleterious 
combination of multiple mutations in sarcomeric contractile and cytoskeletal protein 
genes rather than by a single mutation. Mechanosensing and mechanotransduction 
proteins are key players in the development of restrictive cardiac pathology. 
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To sum up the data unveiled by papers discussed above, desmin-related myopathy 
diagnosis should be concurrently based on clinical phenotype, biopsy histological 
studies, and be genetically proven. When exploring DES modifications one cannot 
rely on mutations leading to severe protein rearrangements and aggregates 
formation only. Non-aggregate substitutions should also be taken into account, since 
they can act as provoking factor to DRM development. It is plausible that SNP 
adverse effect determined by co-existence of changes in multiple genes. These genes 
commonly belong to the families of sarcomeric contractile and cytoskeletal proteins, 
nuclear membrane, and outer mitochondria membrane-associated proteins. 
4.2 PAPER IV: PRIMARY MURINE MYOTUBES AS A MODEL FOR 
INVESTIGATING MUSCULAR DISTROPHY 
The particular interest of this paper was establishment of a robust and relevant 
cellular model to perform functional studies of DES mutations, with emphasis on 
mitochondria. The model should meet the following requirements: availability, ease 
of cultivation, ability to undergo lentiviral genetic modifications, and demonstrate 
high level of similarity to mature muscles. We compared primary adult muscle 
fibers with myotubes formed upon satellite cells fusion. We assessed their 
morphological and physiological properties and analyzed the ability of cells to 
undergo LV genetic modification. We demonstrated that primary myotubes 
resembled primary adult muscle fibers in terms of morphology and physiology. 
Primary myotubes expressed myosin and desmin filaments with the typical cross-
striated pattern found in adult muscle fibres. Mitofusin-2 was expressed 
throughout the cytoplasm of myotubes with no apparent cross-striation, indicating 
that the adult organization of mitochondria had not yet occurred. RyR staining in 
primary myotubes was found throughout the sarcoplasm indicating an extensive 
sarcoplasmic reticulum. Primary myotubes were able to contract and to release 
sarcoplasmic calcium in response to electrical and chemical stimulation indicating 
a functional excitation-contraction coupling pathway linking L-type channel 
activation and the RyR in the sarcoplasmic reticulum. Patch-clamp studies showed 
the presence of Ca2+ currents in plasma membrane of primary myotubes, although 
the L-type Ca2+ current density was less in myotubes than in adult muscle fibers. 
Furthermore, primary myotubes, in contrast to muscle fibers, successfully 
underwent genetic modification via LV transduction and expressed the encoded 
proteins in 72 hours after transduction for at least 14 days. We concluded that 
satellite cells constitute a promising cell model for further experiments aimed at 
exploring calcium pathways involved in muscle dystrophies caused by mutations in 
miscellaneous genes. Thus, this model was recruited for further functional studies 
of DES mutations.  
4.3 PAPER V: AGGREGATE-PRONE DESMIN MUTATIONS IMPAIR 
MITOCHONDRIAL CALCIUM UPTAKE IN PRIMARY MYOTUBES 
Desmin-mitochondria interactions were previously demonstrated in numerous 
studies. It has been explicitely shown that desmin filaments participate in 
mitochondrial anchoring within the cell, and localize them in areas of energy needs, 
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thus providing crosstalk between mechanochemical signaling and metabolism (Fo 
review see 109). The aim of the current paper was to examine the effect of two types 
of desmin point mutations (aggregate-prone versus non-aggregate-prone) on 
mitochondrial calcium uptake. Four mutations, all found in patients with 
myopathy/cardiomyopathy, resulting in different degree of desmin aggregate 
formation, were analyzed. Our results revealed that mitochondrial capacity to take 
up calcium depended on desmin conformation within the muscle cells and was 
altered by desmin structural changes, and the degree of this effect depended on the 
type of desmin mutation. Aggregate-prone mutations demonstrated a considerable 
decrease in mitochondrial calcium upon both electrical and chemical stimulation 
when compared to control cells. Cells carrying desmin gene WT did not differ from 
non-transduced cells in the extent of mitochondrial calcium uptake, as well as cells 
carrying non-aggregate desmin gene mutations. Resting [Ca2+]i as well as post-
stimulation tetanic [Ca2+]i were significantly higher in cells carrying aggregate 
mutation than in WT cells, while measurement of [Ca2+]i did not reveal differences in 
peak concentrations at electrical stimulations between cells expressing WT or 
mutant desmin gene. Therefore, we concluded that mutations in desmin gene had no 
impact on evoked SR calcium release, and decreased [Ca2+]mit in mutant cells was 
due to the insufficient mitochondrial uptake in cells carrying aggregate desmin gene 
mutations, rather than to changes in SR release. The principal roles of mitochondrial 
calcium include regulation of ATP production, modulation of cytosolic calcium 
concentration in some cells such as cardiomyocytes, and initiating apoptosis upon 
highly increased [Ca2+]mit. Therefore, decreased mitochondrial calcium in desmin 
mutant cells could be expected to lead to a decline in ATP production with 
consequent effects on energy turnover and a shift in intracellular calcium 
homeostasis—key events in the development of cardiomyopathies and arrhythmias. 
Given the knowledge of desmin and mitochondria connections, we hypothesize that 
the observed effect of desmin mutations on mitochondrial calcium uptake might be 
the result of disruption of the organelle’s spatial orientation. Due to the altered 
desmin filamentous network, mitochondria could lose their normal positioning with 
respect to the SR (Fig. 4).  
 
Figure 4. Proposed model of disturbed interaction between mitochondria and sarcoplasmic reticulum 
(SR) in the presence of desmin aggregates (adapted from Smolina et al., Cell Calcium. 2014; 56: 269-
275, (176); republished with permission).  
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4.4 UNPUBLISHED RESULTS: DESMIN MUTATIONS DEPRESS 
MITOCHONDRIAL METABOLISM 
Our data have demonstrated decreased mitochondrial calcium levels in muscle cells 
carrying aggregate desmin gene mutations. It was speculated that decreased 
mitochondrial calcium might affect mitochondrial respiratory function, e.g. 
respiration parameters expressed as oxygen consumption rate (OCR). Mitochondrial 
respiration is the process of conversion of energy of taken up substrates into the 
production of ATP through enzymatically-mediated reactions. It takes place in 
mitochondrial matrix and mitochondrial inner membrane, and is important 
component of cellular metabolism. 
To extend knowledge of the impact of desmin mutations on cellular metabolism Cell 
Mito Stress Test (Seahorse Bioscience, USA) experiments were performed. Seahorse 
equipment allows measuring oxygen consumption in living cells and estimate key 
parameters of mitochondrial respiration in real-time mode. Four key mitochondrial 
respiration parameters were measured according to the manufacturer’s protocol—
basal OCR, ATP-linked (non-phosphorylating) OCR, maximal OCR, and non-
mitochondrial OCR. Each experiment encompassed six experimental groups 
corresponding to (i) non-transduced cells and cells transduced via LV encoded (ii) 
Des WT, (iii) Des L345P, (iv) Des A357P, (v) Des L370P, (vi) Des D399Y with 8–16 
technical replicates per group. We normalized obtained data to the basal OCR level 
due to the obstacle of protein normalization. One-way ANOVA was employed to 
evaluate statistical significance, with p<0.05 considered significant. Tukey's post-
hoc analysis was used to compare individual groups. We demonstrated that all cell 
types had similar bioenergetic profiles (Fig. 5(a)): decreasing OCR after oligomycin 
application, rapid OCR increase following FCCP application, and drop of OCR after 
rotenone/antimycin application. We showed that it was only maximal OCR that 
declined in the presence of desmin mutations; all other parameters did not display 
any significant difference between cells expressing endogenous Des or various 
forms of exogenous Des. Relative increase of OCR after FCCP application was 1.95 
± 0.09 for non-transduced cells, 2.36 ± 0.09 for Des WT, 1.85 ± 0.12 for Des 
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dramatically. Furthermore, it was found that only cells expressing mutant desmin 
had relative increase of maximal OCR less than one, implying lack of spare 
respiratory capacity in some of these cells (Fig. 5(c)). [Ca2+]mit activates several key 
enzymes in the mitochondrial matrix resulting in stimulation of ATP production 
(177–179), often through modulation of nitric oxide level and oxygen consumption 
rates (180), recent findings confirmed dose-dependent effect of calcium ions on 
muscle oxidative phosphorylation cascade (181). Therefore, we assumed that 
impaired mitochondrial calcium uptake might confine mitochondrial respiration 
parameters. We showed that in the presence of desmin mutations maximal OCR 
was decreased in comparison to cells harbouring Des WT. 
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Figure 5. Mitochondrial respiration in primary myotubes harboring endogenous desmin (Cntrl) or 
various exogenous desmin variants (a) cells bioenergetic profiling obtained after application of 
mitochondrial inhibitors and reflecting four main parameters of mitochondrial respiration, three 
measurements for each parameter: [1–3] basal OCR, [4–6] non-phosphorylating OCR (after 
oligomycin to inhibit ATP synthase), [7–9] maximal OCR (after FCCP to uncouple the IMM), [10–
12] non-mitochondrial OCR (after rotenone/antimycin A to inhibit complexes I/III). OCR data were 
normalized to the basal OCR level; Dot plots represent selected measurements for each parameter: 
(b) [6] non-phosphorylating OCR; (c) [7] maximal OCR; (d) [12] non-mitochondrial OCR. Data 
represent means ± SEM of 3 independent experiments: *p < 0.05 VS Des WT, ** p < 0.01 VS Des 
WT; ns—no significance difference. 
We demonstrated spare respiratory capacity rate declining as well. These results 
are in agreement with previously established reduction of maximal rate of ADP-
stimulated oxygen consumption in desmin-null cardiac and soleus muscles 
compared with controls measured in situ (59). It is of interest to note that 
measurement of oxygen consumption in isolated mitochondria from control and 
desmin-null mice did not show any variance in ADP-stimulated, ADP-limited, or 
uncoupled respiration rates (59), thus confirming the importance of surrounding 
environment for proper mitochondria functioning. On the other hand, our results 
condratict recently reported data obtained using mice lacking mitochondrial 
calcium uniporter-mediated calcium entry in mitochondria but exhibiting elevated 
or unaltered levels of oxygen consumption (182). This might be explained by the 
fact that measurements were performed on the whole hearts or isolated 
mitochondria, whereas in our experiments mitochondria were analysed in culture 
of myotubes. Moreover, it might be inferred that not only [Ca2+]mit, but also other 
mitochondrial regulating functions are impaired in conjunction with desmin gene 
mutations. It is plausible that the site of desmin-mitochondrial interplay lost its 
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correct spatial orientation, thus affecting other participants of these interactions as 
well. As discussed by Capetanaki et al. (109), desmin interacts with mitochondria at 
contact sites, where proteins responsible for mitochondria biogenesis, morphology, 
and functions are located, e.g. VDAC channels, ANT, and the MICOS complex. 
Spare respiratory capacity is a characteristic of cell bioenergetics reflecting the 
ability of cells to respond to rapid changes in energy demand, encompassing 
substrate supply and electron transport chain performance and resulting in the 
production of extra ATP molecules. Assessment of spare respiratory capacity allows 
defining the bioenergetic limits of the cell that is of a special importance for muscle 
cells undergoing high ATP consumption. The lack of spare respiratory capacity 
implies mitochondrial dysfunction that might be not obvious in normal conditions, 
however becomes overt under the load (183). Moreover, insufficiency of spare 
respiratory capacity was shown to be a hallmark of heart pathologies, e.g. heart 
failure (184,185). Several explanations were proposed for decreased maximal OCR 
and reserve respiration capacity: decreased substrate availability, decreased 
mitochondrial mass, poor electron transport chain integrity (186). Based on our 
and other’s findings, we on the following explanations: declined functions of 
enzymes–participants of respiratory chain due to the impaired mitochondrial 
calcium uptake discussed above, and mitochondrial ADP consumption dependence 
on cytoskeletal components as was showed earlier by Kay et al. (187), Appaix et al. 
(188), and Varikmaa et al. (189).  
4.5 LIMITATIONS OF THE STUDY 
In this section limitations are specified that might impact on our findings and our 
competence in the approach to address the research questions raised. The main 
limitation presents in the majority of studies in this thesis is the application of 
models, for which the relevance may be debated. We recruited primary murine 
satellite cells isolated from the soleus muscle as the cell model, and the cell genome 
was modified via LV transduction. The are several principal limitations regarding 
this model. The first—differences between in vitro and in vivo studies. In vivo studies 
are more preferable over in vitro studies, since they provide better insights and allow 
investigation of complex interactions in disease pathology at organismal level. The 
following limitations concern differences between murine and human muscle 
physiology. Muscles, being a heterogenic tissue, display a high diversity in fiber types 
content resulting in variation of muscle physiological properties between species. 
Further, fiber size matters, which is much smaller in mouse compared to human. 
Last, TG mouse model carrying the mutation resulted in severe clinical manifestation 
in human, e.g. DMD gene mutations, might display relatively benign phenotype. The 
final limitation refers to the stochastics mode of LV genomic integration. LV belong 
to the retroviruses, and are able to the genome integration. However, the pattern of 
integration is unpredictable, and might lead to the randomic impairment of gene 
transcription. In order to overcome previously stated limitations, TG mouse model 
might be used for each examined mutation. However, this approach is costly and 
time-consuming. Satellite cells obtained from the patients might be applied to 
increase the relevance of the study, but biopsy material was difficult to access in our 
studies. Therefore, despite that limitations, we used murine primary satellite cells 
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due to the following reasons: ease of cell isolation, genome modification, cultivation, 
differentiation, and the high level of similarity between primary myotubes and adult 
myofibers (190); proven molecular resemblance of murine soleus muscle to human 
skeletal muscles (191); and absense of overt adverse effects of LV transduction on the 
muscle cell physiology (190). In the future studies we plan to utilize induced 
pluripotent stem cells (iPS), obtained from the patient carrying a mutation, as well as 
from the healthy donors as a control. These iPSc will be differentiated into 
cardiomyocytes and undergo further investigations. We assume this cell model will 
be relevant for studying the role of desmin mutations in development of the 
cardiomyopathy phenotype of DRM. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
The principal goal of current thesis was to evaluate the role of intermediate filament 
desmin in the development of desmin-related myopathy (DRM), with an emphasis 
on development of cardiomyopathy. To address this goal we analyzed in different 
systems the effect of various types of DES mutations. First, we analyzed the clinical 
course of a patient carrying a DES splice-site mutation (IVS3+1G ->A), resulting in 
DRM with transition of phenotypes: from a hypertrophic to a restrictive and dilated 
cardiomyopathy. Next, we continued with a population study in order to assess the 
prevalence of DES A213V, the significance of which was unknown. We found the 
DES A213V substitution to be a disease-modifying polymorphism with 
characteristics of a conditional mutation, rather than a primary disease-related 
mutation. Further, NGS approach was applied to unveil mutant genes underlying 
RCMP, one of cardiac DRM manifestation. By help of the high-throughput sequence 
technologies it became apparent that for most patients with RCMP it was not single 
disease-related mutation, but rather a combination of two or more disease-related–
disease-modifying or diseases-related–disease-related variants that underlie the 
development of RCMP. To perform functional studies of DES mutations, we 
established a robust cell model—primary myotubes, demonstrating high levels of 
morphological and physiological similarity with mature muscle fibers and easily 
undergoing genome modification via lentiviral transduction. Therefore, we adopted 
it to conduct functional studies, aiming at comparing effects of aggregate-prone 
and non-aggregate-prone DES mutations on mitochondrial calcium uptake and 
respiration parameters. We found that aggregate-prone mutations resulted in 
decline of mitochondrial calcium uptake, as well as decreased maximal oxygen 
consumption rate (OCR) and spare respiratory capacity. However, non-aggregate-
prone mutations did not disturb mitochondrial calcium, but still reduced maximal 
OCR and depressed spare respiratory capacity.  
Mechanosensing and mechanotransduction functions of cytoskeletal proteins are of 
great interest today. Current findings strongly support the notion that diseases 
associated with certain mutations of genes encoding cytoskeletal proteins cannot be 
solely attributed to structural defects; but rather concern also wide range of other 
functions, organelle positioning, and signaling. Our data confirmed this perception 
for desmin. The finding that both aggregate-prone and non-aggregate-prone 
mutations influenced mitochondrial bioenergetics indicates that not only 
intermediate filament polymer formation contributes to the disease development.  
Intriguing results were obtained from NGS analysis of patients with RCMP. Fifty 
percent of the genotype-positive patients carried two or more combined mutations. 
Most gene products of these combinations belonged to one of four functional groups: 
(i) sarcomeric contractile proteins, (ii) mechanosensing Z-disc proteins, (iii) nuclear 
membrane, or (iv) outer mitochondrial membrane proteins. This may imply that 
RCMP development is triggered by the combination of several mutations in 
mechanosensing and mechanotransduction proteins. The existence of multiple 
mutations, other than in the DES, may also explain the varying DES A213V effect on 
patients. Moreover, relatively mild effects of DES mutations in vitro studies in 
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comparison to those observed in patients could be linked to this as well. In line 
with this it may be speculated that studying cells obtained directly from a patient 
with DRM, harbouring the entire genetic background would reveal greater 
differences in mitochondrial functions between DES WT and DES mutants. 
In conclusion: 
1. Distortion of desmin mechanotransduction functions play an important role 
in DRM onset, affecting mitochondrial bioenergetics properties. The impact 
of aggregate-prone mutations was greater than of non-aggregate-prone, 
implying increased deleterious effect of desmin aggregates. 
2. A combination of mutations in mechanosensing and mechanotransduction 
protein genes, rather than a single mutation predisposes to development of 
RCMP.  
Further studies are necessary for detailed understanding of mitochondrial 
physiology in the presence of various desmin mutations. Such future analyses may 
include the following experiments. Estimation of the proximity between 
mitochondria and sarcoplasmic reticulum in order to validate the proposed model 
about mitochondrial spatial orientation within the cells harbouring desmin 
aggregate-prone mutations. Further, to estimate mitochondrial fusion-fission due to 
the known fact of mitochondrial dysfunction to result in increase in mitochondrial 
number. In addition, to estimate mitochondrial membrane potential and ADP/ATP 
ratio, thus evaluating the efficiency of mitochondrial respiratory activity. To increase 
the relevance of our studies we plan to use not only primary myotubes, but also iPS 
obtained from the patient carrying DES mutation and differentiated into 
cardiomyocytes. 
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